Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and-or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study – Madrigal Medical Affairs

Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and-or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Oral Presentation

File size: 1.02 MB

Created: 26-11-2024

Updated: 26-11-2024

Hits: 26

Download Preview